At a glance
ClinicalIndex Comparison RecordN/ACompleted· 20 enrolled
Drug / intervention
cabozantinib-s-malate +4 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Pilot Trial of Oral Cabozantinib/XL184 in Metastatic Castrate Resistant Prostate Cancer to Explore the Changes in Bone and Tumor Imaging Related Pathways
In Brief
A clinical study evaluating cabozantinib-s-malate, fluorine F 18 d-FMAU, and 3 other interventions for Adenocarcinoma of the Prostate and 3 related conditions. Completed, enrolled 20 participants across 1 site.
Detailed Summary
This pilot clinical trial studies cabozantinib-s-malate in treating patients with hormone-resistant metastatic prostate cancer. Cabozantinib-s-malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage IV Prostate Cancer
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartMar 2013
First PostedMar 2013
Primary CompletionJan 2019
Study CompletionJun 2019
TodayJul 2026
First PostedMar 18, 2013
Enrollment StartMar 1, 2013
Primary CompletionJan 18, 2019
Study CompletionJun 18, 2019
TodayJul 2, 2026
Enrollment to primary: 5.9 yearsPosted 13.3 years ago
Interventions
cabozantinib-s-malatedrug
Given PO
fluorine F 18 d-FMAUradiation
Undergo 18F PET/FMAU PET scan
positron emission tomographyprocedure
Undergo 18F PET/FMAU PET scan
pharmacological studyother
Correlative studies
laboratory biomarker analysisother
Correlative studies